These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 31133586)

  • 1. Treatment as prevention for hepatitis C virus in Pakistan: mathematical modelling projections.
    Ayoub HH; Abu-Raddad LJ
    BMJ Open; 2019 May; 9(5):e026600. PubMed ID: 31133586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
    Ayoub HH; Abu-Raddad LJ
    J Viral Hepat; 2017 Jun; 24(6):486-495. PubMed ID: 28039923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaling up prevention and treatment towards the elimination of hepatitis C: a global mathematical model.
    Heffernan A; Cooke GS; Nayagam S; Thursz M; Hallett TB
    Lancet; 2019 Mar; 393(10178):1319-1329. PubMed ID: 30704789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curbing the hepatitis C virus epidemic in Pakistan: the impact of scaling up treatment and prevention for achieving elimination.
    Lim AG; Qureshi H; Mahmood H; Hamid S; Davies CF; Trickey A; Glass N; Saeed Q; Fraser H; Walker JG; Mukandavire C; Hickman M; Martin NK; May MT; Averhoff F; Vickerman P
    Int J Epidemiol; 2018 Apr; 47(2):550-560. PubMed ID: 29309592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined treatment and prevention strategies for hepatitis C virus elimination in the prisons in New South Wales: a modelling study.
    Bretaña NA; Gray RR; Cunningham EB; Betz-Stablein B; Ribeiro R; Graw F; Luciani F; Lloyd AR
    Addiction; 2020 May; 115(5):901-913. PubMed ID: 31633853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment as prevention for hepatitis C virus in the Middle East and North Africa: a modeling study.
    Ayoub HH; Mahmud S; Chemaitelly H; Abu-Raddad LJ
    Front Public Health; 2023; 11():1187786. PubMed ID: 37521971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Characterizing the temporal evolution of the hepatitis C virus epidemic in Pakistan.
    Ayoub HH; Al Kanaani Z; Abu-Raddad LJ
    J Viral Hepat; 2018 Jun; 25(6):670-679. PubMed ID: 29345847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scaling-up HCV prevention and treatment interventions in rural United States-model projections for tackling an increasing epidemic.
    Fraser H; Zibbell J; Hoerger T; Hariri S; Vellozzi C; Martin NK; Kral AH; Hickman M; Ward JW; Vickerman P
    Addiction; 2018 Jan; 113(1):173-182. PubMed ID: 28734093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Australia on track to achieve WHO HCV elimination targets following rapid initial DAA treatment uptake: A modelling study.
    Kwon JA; Dore GJ; Grebely J; Hajarizadeh B; Guy R; Cunningham EB; Power C; Estes C; Razavi H; Gray RT;
    J Viral Hepat; 2019 Jan; 26(1):83-92. PubMed ID: 30267593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and primary prevention in people who inject drugs for chronic hepatitis C infection: is elimination possible in a high-prevalence setting?
    Gountas I; Sypsa V; Anagnostou O; Martin N; Vickerman P; Kafetzopoulos E; Hatzakis A
    Addiction; 2017 Jul; 112(7):1290-1299. PubMed ID: 28107585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study.
    Walker JG; Kuchuloria T; Sergeenko D; Fraser H; Lim AG; Shadaker S; Hagan L; Gamkrelidze A; Kvaratskhelia V; Gvinjilia L; Aladashvili M; Asatiani A; Baliashvili D; Butsashvili M; Chikovani I; Khonelidze I; Kirtadze I; Kuniholm MH; Otiashvili D; Sharvadze L; Stvilia K; Tsertsvadze T; Zakalashvili M; Hickman M; Martin NK; Morgan J; Nasrullah M; Averhoff F; Vickerman P
    Lancet Glob Health; 2020 Feb; 8(2):e244-e253. PubMed ID: 31864917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Enhanced Screening and Treatment on Hepatitis C in the United States.
    Durham DP; Skrip LA; Bruce RD; Vilarinho S; Elbasha EH; Galvani AP; Townsend JP
    Clin Infect Dis; 2016 Feb; 62(3):298-304. PubMed ID: 26628566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis.
    Lim AG; Scott N; Walker JG; Hamid S; Hellard M; Vickerman P
    PLoS Med; 2021 Oct; 18(10):e1003818. PubMed ID: 34665815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.
    Harris RJ; Harris HE; Mandal S; Ramsay M; Vickerman P; Hickman M; De Angelis D
    J Viral Hepat; 2019 May; 26(5):541-551. PubMed ID: 30663179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of screening and treatment using direct-acting antivirals for chronic Hepatitis C virus in a primary care setting in Karachi, Pakistan.
    Mafirakureva N; Lim AG; Khalid GG; Aslam K; Campbell L; Zahid H; Van den Bergh R; Falq G; Fortas C; Wailly Y; Auat R; Donchuk D; Loarec A; Coast J; Vickerman P; Walker JG
    J Viral Hepat; 2021 Feb; 28(2):268-278. PubMed ID: 33051950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A; Leclerc P; Morissette C; Bruneau J; Roy É; Tran VC; Yazdanpanah Y; Cox J
    BMC Infect Dis; 2017 Feb; 17(1):162. PubMed ID: 28222681
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the hepatitis C virus epidemic in Pakistan.
    Mahmud S; Al Kanaani Z; Abu-Raddad LJ
    BMC Infect Dis; 2019 Sep; 19(1):809. PubMed ID: 31521121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strategies to manage hepatitis C virus infection disease burden - volume 3.
    Alfaleh FZ; Nugrahini N; Matičič M; Tolmane I; Alzaabi M; Hajarizadeh B; Valantinas J; Kim DY; Hunyady B; Abaalkhail F; Abbas Z; Abdou A; Abourached A; Al Braiki F; Al Hosani F; Al Jaberi K; Al Khatry M; Al Mulla MA; Al Quraishi H; Al Rifai A; Al Serkal Y; Alam A; Alashgar HI; Alavian SM; Alawadhi S; Al-Dabal L; Aldins P; Alghamdi AS; Al-Hakeem R; Aljumah AA; Almessabi A; Alqutub AN; Alswat KA; Altraif I; Andrea N; Assiri AM; Babatin MA; Baqir A; Barakat MT; Bergmann OM; Bizri AR; Chaudhry A; Choi MS; Diab T; Djauzi S; El Hassan ES; El Khoury S; Estes C; Fakhry S; Farooqi JI; Fridjonsdottir H; Gani RA; Ghafoor Khan A; Gheorghe L; Goldis A; Gottfredsson M; Gregorcic S; Gunter J; Hamid S; Han KH; Hasan I; Hashim A; Horvath G; Husni R; Jafri W; Jeruma A; Jonasson JG; Karlsdottir B; Kim YS; Koutoubi Z; Lesmana LA; Liakina V; Lim YS; Löve A; Maimets M; Makara M; Malekzadeh R; Memon MS; Merat S; Mokhbat JE; Mourad FH; Muljono DH; Nawaz A; Olafsson S; Priohutomo S; Qureshi H; Rassam P; Razavi H; Razavi-Shearer D; Razavi-Shearer K; Rozentale B; Sadik M; Saeed K; Salamat A; Salupere R; Sanai FM; Sanityoso Sulaiman A; Sayegh RA; Schmelzer JD; Sharara AI; Sibley A; Siddiq M; Siddiqui AM; Sigmundsdottir G; Sigurdardottir B; Speiciene D; Sulaiman A; Sultan MA; Taha M; Tanaka J; Tarifi H; Tayyab G; Ud Din M; Umar M; Videčnik-Zorman J; Yaghi C; Yunihastuti E; Yusuf MA; Zuberi BF; Blach S
    J Viral Hepat; 2015 Dec; 22 Suppl 4():42-65. PubMed ID: 26513447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of the Feasibility and Cost of Hepatitis C Elimination in Pakistan.
    Chhatwal J; Chen Q; Wang X; Ayer T; Zhuo Y; Janjua NZ; Kanwal F
    JAMA Netw Open; 2019 May; 2(5):e193613. PubMed ID: 31074817
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.